|
1
|
Xiong G, Guo H, Ge X, Xu X, Yang X, Yang
K, Jiang Y and Bai Y: Decoy receptor 3 expression in esophageal
squamous cell carcinoma: correlation with tumour invasion and
metastasis. Biomarkers. 16:155–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Colucci S, Brunetti G, Mori G, Oranger A,
Centonze M, Mori C, Cantatore FP, Tamma R, Rizzi R, Liso V, Zallone
A and Grano M: Soluble decoy receptor 3 modulates the survival and
formation of osteoclasts from multiple myeloma bone disease
patients. Leukemia. 23:2139–2146. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Connor JP and Felder M: Ascites from
epithelial ovarian cancer contain high levels of functional decoy
receptor 3 (DcR3) and is associated with platinum resistance.
Gynecol Oncol. 111:330–335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiong G, Guo H, Wang K, Hu H, Wang D, Xu
X, Guan X, Yang K and Bai Y: Polymorphisms of decoy receptor 3 are
associated with risk of esophageal squamous cell carcinoma in
Chinese Han. Tumour Biol. 31:443–449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen J, Zhang L and Kim S: Quantification
and detection of DcR3, a decoy receptor in TNFR family. J Immunol
Methods. 285:63–70. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu Y, Han B, Sheng H, Lin M, Moore PA,
Zhang J and Wu J: Clinical significance of detecting elevated serum
DcR3/TR6/M68 in malignant tumor patients. Int J Cancer.
105:724–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsuji S, Hosotani R, Yonehara S, et al:
Endogenous decoy receptor 3 blocks the growth inhibition signals
mediated by Fas ligand in human pancreatic adenocarcinoma. Int J
Cancer. 106:17–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Macher-Goeppinger S, Aulmann S, Wagener N,
Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S,
Autschbach F, Schirmacher P and Roth W: Decoy receptor 3 is a
prognostic factor in renal cell cancer. Neoplasia. 10:1049–1056.
2008.PubMed/NCBI
|
|
9
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar
|
|
10
|
Lee WS, Kang M, Baek JH, Lee JI and Ha SY:
Clinical impact of tumor-infiltrating lymphocytes for survival in
curatively resected stage IV colon cancer with isolated liver or
lung metastasis. Ann Surg Oncol. 20:697–702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jagani H, Rao JV, Palanimuthu VR,
Hariharapura RC and Gang SA: A nanoformulation of siRNA and its
role in cancer therapy: in vitro and in vivo evaluation. Cell Mol
Biol Lett. 18:120–136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okamoto S, Amaishi Y, Goto Y, Ikeda H,
Fujiwara H, Kuzushima K, Yasukawa M, Shiku H and Mineno J: A
promising vector for TCR gene therapy: differential effect of
siRNA, 2A peptide, and disulfide bond on the introduced TCR
expression. Mol Ther Nucleic Acids. 1:e632012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baker AM, Cox TR, Bird D, Lang G, Murray
GI, Sun XF, Southall SM, Wilson JR and Erler JT: The role of lysyl
oxidase in SRC-dependent proliferation and metastasis of colorectal
cancer. J Natl Cancer Inst. 103:407–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gulhati P, Cai Q, Li J, Liu J, Rychahou
PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T and Evers BM: Targeted
inhibition of mammalian target of rapamycin signaling inhibits
tumorigenesis of colorectal cancer. Clin Cancer Res. 15:7207–7216.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Binkhathlan Z and Alshamsan A: Emerging
nanodelivery strategies of RNAi molecules for colon cancer therapy:
preclinical developments. Ther Deliv. 3:1117–1130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu B, Zhou H, Hu L, Mu Y and Wu Y:
Involvement of PKCα activation in TF/VIIa/PAR2-induced
proliferation, migration, and survival of colon cancer cell SW620.
Tumour Biol. 34:837–846. 2013.
|
|
17
|
Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and
Kwon BS: A newly identified member of tumor necrosis factor
receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J
Biol Chem. 274:13733–13736. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi G, Mao J, Yu G, Zhang J and Wu J:
Tumor vaccine based on cell surface expression of DcR3/TR6. J
Immunol. 174:4727–4735. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takahama Y, Yamada Y, Emoto K, Fujimoto H,
Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T and Nakajima Y: The
prognostic significance of overexpression of the decoy receptor for
Fas ligand (DcR3) in patients with gastric carcinomas. Gastric
Cancer. 5:61–68. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bai C, Connolly B, Metzker ML, Hilliard
CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP and
Caskey CT: Overexpreasion of M68/DcR3 in human gastrointestinal
tract tumors independent of gene amplificalion and its location in
a four-gene cluster. Proc Natl Acad Sci USA. 97:1230–1235. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Flokman J and D’amore PA: Blood vessel
formation: what is its molecular basis? Cell. 87:1153–1155. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lepelletier Y, Camara-Clayette V, Jin H,
Hermant A, Coulon S, Dussiot M, et al: Prevention of mantle
lymphoma tumor by routing transferrin receptor lysosomal
compartment. Cancer Res. 67:1145–1154. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stacker SA, Caesar C, Baldwin ME, et al:
VEGF-D promotes the metastatic spread of tumor cells via the
lymphatics. Nat Med. 7:186–191. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagy JA, Vasile E, Feng D, et al: Vascular
permeability factor/vascular endothelial growth factor induces
lymphangiogenesis as well as angiogenesis. J Exp Med.
196:1497–1506. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
George ML, Tutton MG, Janssen F, Arnaout
A, Abulafi AM, Eccles SA and Swift RI: VEGF-A, VEGF-C, and VEGF-D
in colorectal cancer progression. Neoplasia. 3:420–427. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL
and Lin WW: Soluble decoy receptor 3 induces angiogenesis by
neutralization of TL1A, a cytokine belonging to tumor necrosis
factor superfamily and exhibiting angiostatic action. Cancer Res.
64:1122–1129. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Egeblad M and Werb Z: New functions for
the matrix metallo-proteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar
|
|
29
|
Gao J, Ding F, Liu Q and Yao Y: Knockdown
of MACC1 expression suppressed hepatocellular carcinoma cell
migration and invasion and inhibited expression of MMP2 and MMP9.
Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hotary KB, Allen ED, Brooks PC, Datta NS,
Long MW and Weiss SJ: Membrane type I matrix metalloproteinase
usurps tumor growth control imposed by the three-dimensional
extracellular matrix. Cell. 114:33–45. 2003. View Article : Google Scholar
|
|
31
|
Yamashita K, Upadhay S, Mimori K, Inoue H
and Mori M: Clinical significance of secreted protein acidic and
rich in cystein in esophageal carcinoma and its relation to
carcinoma progression. Cancer. 97:2412–2419. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Koyama H, Iwata H, Kuwabara Y, Iwase H,
Kobayashi S and Fujii Y: Gelatinolytic activity of matrix
metalloproteinase-2 and -9 in oesophageal carcinoma; a study using
in situ zymography. Eur J Cancer. 36:2164–2170. 2000. View Article : Google Scholar : PubMed/NCBI
|
